“a question: if mild and moderate patients are treated and do not get hospitalized, where are we?”
I wouldn’t be worried about the future supply of moderate to severe COVID-19 cases, if that’s the point of your question.
We’ve already seen in this very message board that the reluctance to embrace safe effective preventive measures will extend to safe effective treatments such as the new Merck/Ridgeback drug.
Whether that population will be any more willing to embrace brilacidin in the unlikely event it shows efficacy in a 120 patient trial is a different question.
I think I’d be tempted to sell my IPIX shares (if I had any) and buy stock in ventilator companies instead. They should be golden, at least until Natural Selection does it thing and that particular market dries up.
News 
Market Data 
Discover 
